Author

Fritz Offner

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Forimtamig, a GPRC5DxCD3 bispecific antibody with a novel 2:1 format, in relapsed/refractory multiple myeloma.

We report the results from a Phase 1 study (NCT04557150) evaluating subcutaneous (SC) forimtamig, a novel GPRC5DxCD3 bispecific antibody with a 2:1 configuration, in relapsed/refractory multiple myeloma (RRMM). After dose-escalation, backfilling at optimized target doses in combination with weekly (step-up: Cycle [C] 1...

Anna Caroline Hasselbalch, Simon J. Harrison, Salomon Manier et al. · Blood Advances · 0 citations

Clinical trial Open access Sep 2026

Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial.

The overall response rate was 95% (95% CI 84-99; 39 of 41 patients), and the most common grade 3-4 adverse events were neutropenia and infections, while epcoritamab showed high activity in first-line treatment for follicular lymphoma.

L. Falchi, J. Vermaat, Joshua D. Brody et al. · The Lancet Haematology · 0 citations